PLCB1

Across TCGA pan-cancer cohorts, PLCB1 Mutation is linked to patient survival in 10 of 34 cancer types, making it a survival-associated PLCB1 data layer compared with 24 for mass-spec protein and 8 for mass-spec protein.

The strongest signal is observed in small cell lung cancer (SCLC), where higher PLCB1 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated PLCB1 expression acts as an unfavorable survival marker, although some lineages such as UCEC and STAD show a favorable association.

SCLC, OV, and LUSC are the cancer types where PLCB1 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
SCLC	DFS	Median	All	0.183	0.637	.001	21	view →
OV	OS	Median	III,IV	0.285	0.836	.001	20	view →
LUSC	OS	Median	III,IV	0.202	0.586	.002	19	view →
DLBC	DFS	Median	II,III,IV	0.065	0.829	<.001	15	view →
LIHC	DFS	Median	II,III,IV	0.086	0.435	<.001	11	view →
UCEC	DFS	Median	All	0.824	0.625	.007	10	view →
SARC	DFS	Median	All	0.150	0.614	<.001	6	view →
STAD	DFS	Median	III,IV	0.857	0.334	.044	3	view →
SKCM	DFS	Median	IV	0.763	0.238	.038	2	view →
BLCA	OS	Median	IV	0.841	0.445	.049	1	view →

Pink = unfavorable, green = favorable. Showing the 10 strongest of 10 lineages.

PLCB1–SCLC (DFS)

Open the SCLC breakdown →